MONDAY, March 11 (HealthDay News) -- For adults with diabetes, use of glucagon-like peptide 1 (GLP-1) analogs is associated with a reduced risk of heart failure hospitalization, all-cause hospitalization, and all-cause mortality, according to a study presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.
Noting that recent studies suggest GLP-1 agents may be protective against heart failure, David Lanfear, M.D., from Henry Ford Hospital in Detroit, and colleagues conducted a retrospective cohort study involving adults with diabetes from a large health system in southeast Michigan. The effect of GLP-1 agents on time to heart failure hospitalization, all-cause hospitalization, and all-cause mortality was assessed for 1,488 new users of GLP-1 agents and 2,939 propensity-matched controls.
Over a median observation period of 663 days, the researchers identified 281 hospitalizations, of which 184 were attributed to heart failure, and 158 deaths. Use of GLP-1 agents correlated with a significantly reduced risk of heart failure hospitalization, all-cause hospitalization, and all-cause mortality (adjusted hazard ratios, 0.56, 0.56, and 0.20, respectively).
"These preliminary results look very promising," Lanfear said in a statement. "However, this was a retrospective study and this subject needs further investigation."
Health News Copyright © 2013 HealthDay. All rights reserved.